AXGN
Axogen Inc.

1,363
Mkt Cap
$836.05M
Volume
788,077.00
52W High
$21.00
52W Low
$9.22
PE Ratio
-171.90
AXGN Fundamentals
Price
$17.77
Prev Close
$18.17
Open
$18.24
50D MA
$16.60
Beta
1.12
Avg. Volume
877,366.19
EPS (Annual)
-$0.2251
P/B
7.41
Rev/Employee
$414,464.60
Loading...
Loading...
News
all
press releases
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc...
PR Newswire·9d ago
News Placeholder
More News
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc...
PR Newswire·19d ago
News Placeholder
CLPT Expands Into Robotic System Supporting Cell and Gene Therapies
ClearPoint's new Robotic Neuro-Navigation System merges proven software with KUKA robotics to boost precision in cell and gene therapy delivery.
Zacks·21d ago
News Placeholder
GEHC Inks License Agreement With Lantheus for Prostate Imaging Agent
GE HealthCare strengthens its radiopharmaceutical portfolio by licensing Lantheus' PSMA PET imaging agent, PYLARIFY, for commercialization in Japan.
Zacks·1mo ago
News Placeholder
Masimo Completes Divestment of Consumer Audio Business to HARMAN
MASI completes sale of Sound United to HARMAN, sharpening focus on core healthcare, boosting margins, and funding buybacks.
Zacks·1mo ago
News Placeholder
Here's Why You Should Add Inogen Stock to Your Portfolio Now
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
Zacks·1mo ago
News Placeholder
Are Medical Stocks Lagging AxoGen (AXGN) This Year?
Here is how AxoGen (AXGN) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
Zacks·2mo ago
News Placeholder
Does AxoGen (AXGN) Have the Potential to Rally 53.1% as Wall Street Analysts Expect?
The mean of analysts' price targets for AxoGen (AXGN) points to a 53.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·2mo ago
News Placeholder
Why Is Axogen Stock Down 15% In Pre-Market Today?
The stock tumbled after the company announced that the U.S. FDA pushed the date of the decision regarding approval for Avance Nerve Graft by three months.
Stocktwits·2mo ago
News Placeholder
Wall Street Analysts Predict a 76.37% Upside in AxoGen (AXGN): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 76.4% in AxoGen (AXGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·3mo ago

Latest AXGN News

View

Advertisement|Remove ads.

Advertisement|Remove ads.